Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic–clonic seizures

Abstract

AbstractObjectiveStatic assignment of participants in randomized clinical trials to placebo or ineffective treatment confers risk from continued seizures. An alternative trial design of time to exceed prerandomization monthly seizure count (T‐PSC) has replicated the efficacy conclusions of traditionally designed trials, with shorter exposure to placebo and ineffective treatment. Trials aim to evaluate efficacy as well as safety and tolerability; therefore, we evaluated whether this T‐PSC design also could replicate the trial's safety and tolerability conclusions.MethodsWe retrospectively applied the T‐PSC design to analyze treatment‐emergent adverse events (TEAEs) from a blinded, placebo‐controlled trial of perampanel for primary generalized tonic–clonic seizures (NCT01393743). The safety analysis set consisted of 81 and 82 participants randomized to perampanel and placebo arms, respectively. We evaluated the incidences of TEAEs, treatment‐related TEAEs, serious TEAEs, and TEAEs of special interest that occurred before T‐PSC relative to those observed during the full‐length trial.ResultsOf the 67 and 59 participants who experienced TEAEs in the perampanel and placebo arms during full‐length trial, 66 (99%) and 54 (92%) participants experienced TEAEs with onset occurring before T‐PSC, respectively. When limited to treatment‐related TEAEs, 55 of 56 (98%) and 32 of 37 (86%) participants reported treatment‐related TEAEs that occurred before T‐PSC in the perampanel and placebo arms, respectively. There were more TEAEs after T‐PSC with placebo as compared to perampanel (Fisher exact odds ratio = 8.6, p = .035), which resulted in overestimation of the difference in TEAE rate. There was a numerical reduction in serious TEAEs (3/13 occurred after T‐PSC, one in placebo and two in perampanel).SignificanceAlmost all TEAEs occurred before T‐PSC. More treatment‐related TEAEs occurred after T‐PSC for participants randomized to placebo than perampanel, which may be due to either a shorter T‐PSC or delayed time to TEAE for placebo.